A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
Fig 2
Probabilities of non-negative responses vs. time (days) for subjects in the HCQ and SOC groups in the multicenter, open-label, randomized controlled trial.
Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care.